These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22569229)

  • 1. Impact of the experimental conditions on drug release from parenteral depot systems: From negligible to significant.
    Delplace C; Kreye F; Klose D; Danède F; Descamps M; Siepmann J; Siepmann F
    Int J Pharm; 2012 Aug; 432(1-2):11-22. PubMed ID: 22569229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug release from PLGA-based microparticles: effects of the "microparticle:bulk fluid" ratio.
    Klose D; Siepmann F; Willart JF; Descamps M; Siepmann J
    Int J Pharm; 2010 Jan; 383(1-2):123-31. PubMed ID: 19748558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
    Klose D; Delplace C; Siepmann J
    Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLGA-based drug delivery systems: importance of the type of drug and device geometry.
    Klose D; Siepmann F; Elkharraz K; Siepmann J
    Int J Pharm; 2008 Apr; 354(1-2):95-103. PubMed ID: 18055140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLGA implants: How Poloxamer/PEO addition slows down or accelerates polymer degradation and drug release.
    Hamoudi-Ben Yelles MC; Tran Tan V; Danede F; Willart JF; Siepmann J
    J Control Release; 2017 May; 253():19-29. PubMed ID: 28284831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug release mechanisms of compressed lipid implants.
    Kreye F; Siepmann F; Siepmann J
    Int J Pharm; 2011 Feb; 404(1-2):27-35. PubMed ID: 21055453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How porosity and size affect the drug release mechanisms from PLGA-based microparticles.
    Klose D; Siepmann F; Elkharraz K; Krenzlin S; Siepmann J
    Int J Pharm; 2006 May; 314(2):198-206. PubMed ID: 16504431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory.
    Faisant N; Akiki J; Siepmann F; Benoit JP; Siepmann J
    Int J Pharm; 2006 May; 314(2):189-97. PubMed ID: 16510257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PLGA microparticles with zero-order release of the labile anti-Parkinson drug apomorphine.
    Regnier-Delplace C; Thillaye du Boullay O; Siepmann F; Martin-Vaca B; Degrave N; Demonchaux P; Jentzer O; Bourissou D; Siepmann J
    Int J Pharm; 2013 Feb; 443(1-2):68-79. PubMed ID: 23313920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled release implants based on cast lipid blends.
    Kreye F; Siepmann F; Zimmer A; Willart JF; Descamps M; Siepmann J
    Eur J Pharm Sci; 2011 May; 43(1-2):78-83. PubMed ID: 21463679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery.
    Kim DH; Martin DC
    Biomaterials; 2006 May; 27(15):3031-7. PubMed ID: 16443270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.
    Xu H; Zhong H; Liu M; Xu C; Gao Y
    Pharmazie; 2011 Sep; 66(9):654-61. PubMed ID: 22026119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment.
    Siepmann J; Elkharraz K; Siepmann F; Klose D
    Biomacromolecules; 2005; 6(4):2312-9. PubMed ID: 16004477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug release mechanisms of cast lipid implants.
    Kreye F; Siepmann F; Willart JF; Descamps M; Siepmann J
    Eur J Pharm Biopharm; 2011 Aug; 78(3):394-400. PubMed ID: 21352913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-situ forming PLGA implants for intraocular dexamethasone delivery.
    Bode C; Kranz H; Siepmann F; Siepmann J
    Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms.
    Guse C; Koennings S; Kreye F; Siepmann F; Goepferich A; Siepmann J
    Int J Pharm; 2006 May; 314(2):137-44. PubMed ID: 16503388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Colloids Surf B Biointerfaces; 2009 Nov; 74(1):340-9. PubMed ID: 19717287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the size of biodegradable microparticles on drug release: experiment and theory.
    Siepmann J; Faisant N; Akiki J; Richard J; Benoit JP
    J Control Release; 2004 Apr; 96(1):123-34. PubMed ID: 15063035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards more realistic in vitro release measurement techniques for biodegradable microparticles.
    Klose D; Azaroual N; Siepmann F; Vermeersch G; Siepmann J
    Pharm Res; 2009 Mar; 26(3):691-9. PubMed ID: 18958404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone implants modified with cyclodextrin: study of drug release in bulk fluid and into agarose gel.
    Hoang Thi TH; Chai F; Leprêtre S; Blanchemain N; Martel B; Siepmann F; Hildebrand HF; Siepmann J; Flament MP
    Int J Pharm; 2010 Nov; 400(1-2):74-85. PubMed ID: 20816734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.